Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure
The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of...
Gespeichert in:
| Veröffentlicht in: | Biochemical and biophysical research communications 2005-12, Vol.338 (4), p.1865-1874 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1874 |
|---|---|
| container_issue | 4 |
| container_start_page | 1865 |
| container_title | Biochemical and biophysical research communications |
| container_volume | 338 |
| creator | Daiber, Andreas Oelze, Matthias Coldewey, Meike Kaiser, K. Huth, C. Schildknecht, S. Bachschmid, M. Nazirisadeh, Y. Ullrich, V. Mülsch, A. Münzel, T. Tsilimingas, N. |
| description | The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound. The antioxidant effects of hydralazine were tested in cell free systems, cultured smooth muscle cells, isolated mitochondria, and isolated vessels. Inhibitory effects on the formation of superoxide and/or peroxynitrite formation were tested using lucigenin and L-012 enhanced chemiluminescence as well as DHE-fluorescence. The peroxynitrite scavenging properties were also assessed by inhibition of nitration of phenol. Prevention of impairment of NO downstream signaling and GTN bioactivation was determined by measurement of P-VASP (surrogate parameter for the activity of the cGMP-dependent kinase-I, cGK-I) and mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Hydralazine dose-dependently decreased the chemiluminescence signal induced by peroxynitrite from SIN-1 and by superoxide from HX/XO in a cell free system, by superoxide in smooth muscle cells and mitochondria acutely challenged with GTN. Moreover, hydralazine inhibited the peroxynitrite-mediated nitration of phenols as well as proteins in smooth muscle cells in a dose-dependent fashion. Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Our results indicate that hydralazine is a highly potent radical scavenger. Thus, the combination with isosorbide dinitrate (ISDN) will favorably influence the nitroso-redox balance in the cardiovascular system in patients with congestive heart failure and may explain at least in part the improvement of prognosis in patients with chronic congestive heart failure. |
| doi_str_mv | 10.1016/j.bbrc.2005.10.106 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68822519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X05023569</els_id><sourcerecordid>68822519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-185d0685f39797d60013a68aed739097b2fcd7499116877499e941709d1445503</originalsourceid><addsrcrecordid>eNp9UU2PFCEQJUbjjqt_wIPh5K1H6A-6SbyYjeuabOJFE2-EhmKnJj3QAr2740_yVy5jT-LNE1DvvaJePULecrbljIsP--04RrOtGeu2f2viGdlwJllVc9Y-JxvGmKhqyX9ekFcp7RnjvBXyJbngoh4kZ_2G_Lk52qgn_Rs9UExU0zk8QHTLRNHvcMQcIg2OzhDD49FjjpiBuhAPOmPwVK-SlHCcgMLjPGm_IoVDMSc6ggeHBvVEwTkwpVTQOYY7H1L5EcujKMAX4AHzjprg7yBlvAe6Ax0zdRqnJcJr8sLpKcGb83lJflx__n51U91--_L16tNtZZquzRUfOsvE0LlG9rK3orhutBg02L6RTPZj7YztWyk5F0N_uoBsec-k5W3bday5JO_XvmXGX0uZRB0wGZiKMwhLUmIY6rrjshDrlWhiWUAEp-aIBx2PijN1Skjt1SkhdUporYkienfuvowHsP8k50gK4eNKgOLxHiGqZMp2DFiMZXvKBvxf_yeG4KVW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68822519</pqid></control><display><type>article</type><title>Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Daiber, Andreas ; Oelze, Matthias ; Coldewey, Meike ; Kaiser, K. ; Huth, C. ; Schildknecht, S. ; Bachschmid, M. ; Nazirisadeh, Y. ; Ullrich, V. ; Mülsch, A. ; Münzel, T. ; Tsilimingas, N.</creator><creatorcontrib>Daiber, Andreas ; Oelze, Matthias ; Coldewey, Meike ; Kaiser, K. ; Huth, C. ; Schildknecht, S. ; Bachschmid, M. ; Nazirisadeh, Y. ; Ullrich, V. ; Mülsch, A. ; Münzel, T. ; Tsilimingas, N.</creatorcontrib><description>The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound. The antioxidant effects of hydralazine were tested in cell free systems, cultured smooth muscle cells, isolated mitochondria, and isolated vessels. Inhibitory effects on the formation of superoxide and/or peroxynitrite formation were tested using lucigenin and L-012 enhanced chemiluminescence as well as DHE-fluorescence. The peroxynitrite scavenging properties were also assessed by inhibition of nitration of phenol. Prevention of impairment of NO downstream signaling and GTN bioactivation was determined by measurement of P-VASP (surrogate parameter for the activity of the cGMP-dependent kinase-I, cGK-I) and mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Hydralazine dose-dependently decreased the chemiluminescence signal induced by peroxynitrite from SIN-1 and by superoxide from HX/XO in a cell free system, by superoxide in smooth muscle cells and mitochondria acutely challenged with GTN. Moreover, hydralazine inhibited the peroxynitrite-mediated nitration of phenols as well as proteins in smooth muscle cells in a dose-dependent fashion. Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Our results indicate that hydralazine is a highly potent radical scavenger. Thus, the combination with isosorbide dinitrate (ISDN) will favorably influence the nitroso-redox balance in the cardiovascular system in patients with congestive heart failure and may explain at least in part the improvement of prognosis in patients with chronic congestive heart failure.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2005.10.106</identifier><identifier>PMID: 16289107</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aldehyde Dehydrogenase - antagonists & inhibitors ; Aldehyde Dehydrogenase, Mitochondrial ; Animals ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Cell Adhesion Molecules - biosynthesis ; Drug Tolerance - physiology ; Free Radical Scavengers - pharmacology ; Heart Failure - drug therapy ; Humans ; Hydralazine ; Hydralazine - pharmacology ; Hydralazine - therapeutic use ; Male ; Microfilament Proteins - biosynthesis ; Mitochondria - drug effects ; Mitochondria - metabolism ; Mitochondrial Proteins - antagonists & inhibitors ; Nitrate tolerance ; Nitroglycerin - pharmacology ; NO signaling ; Organic nitrates ; Oxidative Stress - drug effects ; Peroxynitrite ; Peroxynitrous Acid - antagonists & inhibitors ; Peroxynitrous Acid - biosynthesis ; Phosphoproteins - biosynthesis ; Prognosis ; Radical scavenger ; Rats ; Rats, Wistar ; Reactive Nitrogen Species - metabolism ; Reactive Oxygen Species - metabolism ; Superoxide</subject><ispartof>Biochemical and biophysical research communications, 2005-12, Vol.338 (4), p.1865-1874</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-185d0685f39797d60013a68aed739097b2fcd7499116877499e941709d1445503</citedby><cites>FETCH-LOGICAL-c354t-185d0685f39797d60013a68aed739097b2fcd7499116877499e941709d1445503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbrc.2005.10.106$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16289107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daiber, Andreas</creatorcontrib><creatorcontrib>Oelze, Matthias</creatorcontrib><creatorcontrib>Coldewey, Meike</creatorcontrib><creatorcontrib>Kaiser, K.</creatorcontrib><creatorcontrib>Huth, C.</creatorcontrib><creatorcontrib>Schildknecht, S.</creatorcontrib><creatorcontrib>Bachschmid, M.</creatorcontrib><creatorcontrib>Nazirisadeh, Y.</creatorcontrib><creatorcontrib>Ullrich, V.</creatorcontrib><creatorcontrib>Mülsch, A.</creatorcontrib><creatorcontrib>Münzel, T.</creatorcontrib><creatorcontrib>Tsilimingas, N.</creatorcontrib><title>Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound. The antioxidant effects of hydralazine were tested in cell free systems, cultured smooth muscle cells, isolated mitochondria, and isolated vessels. Inhibitory effects on the formation of superoxide and/or peroxynitrite formation were tested using lucigenin and L-012 enhanced chemiluminescence as well as DHE-fluorescence. The peroxynitrite scavenging properties were also assessed by inhibition of nitration of phenol. Prevention of impairment of NO downstream signaling and GTN bioactivation was determined by measurement of P-VASP (surrogate parameter for the activity of the cGMP-dependent kinase-I, cGK-I) and mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Hydralazine dose-dependently decreased the chemiluminescence signal induced by peroxynitrite from SIN-1 and by superoxide from HX/XO in a cell free system, by superoxide in smooth muscle cells and mitochondria acutely challenged with GTN. Moreover, hydralazine inhibited the peroxynitrite-mediated nitration of phenols as well as proteins in smooth muscle cells in a dose-dependent fashion. Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Our results indicate that hydralazine is a highly potent radical scavenger. Thus, the combination with isosorbide dinitrate (ISDN) will favorably influence the nitroso-redox balance in the cardiovascular system in patients with congestive heart failure and may explain at least in part the improvement of prognosis in patients with chronic congestive heart failure.</description><subject>Aldehyde Dehydrogenase - antagonists & inhibitors</subject><subject>Aldehyde Dehydrogenase, Mitochondrial</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Cell Adhesion Molecules - biosynthesis</subject><subject>Drug Tolerance - physiology</subject><subject>Free Radical Scavengers - pharmacology</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Hydralazine</subject><subject>Hydralazine - pharmacology</subject><subject>Hydralazine - therapeutic use</subject><subject>Male</subject><subject>Microfilament Proteins - biosynthesis</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - metabolism</subject><subject>Mitochondrial Proteins - antagonists & inhibitors</subject><subject>Nitrate tolerance</subject><subject>Nitroglycerin - pharmacology</subject><subject>NO signaling</subject><subject>Organic nitrates</subject><subject>Oxidative Stress - drug effects</subject><subject>Peroxynitrite</subject><subject>Peroxynitrous Acid - antagonists & inhibitors</subject><subject>Peroxynitrous Acid - biosynthesis</subject><subject>Phosphoproteins - biosynthesis</subject><subject>Prognosis</subject><subject>Radical scavenger</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Reactive Nitrogen Species - metabolism</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Superoxide</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2PFCEQJUbjjqt_wIPh5K1H6A-6SbyYjeuabOJFE2-EhmKnJj3QAr2740_yVy5jT-LNE1DvvaJePULecrbljIsP--04RrOtGeu2f2viGdlwJllVc9Y-JxvGmKhqyX9ekFcp7RnjvBXyJbngoh4kZ_2G_Lk52qgn_Rs9UExU0zk8QHTLRNHvcMQcIg2OzhDD49FjjpiBuhAPOmPwVK-SlHCcgMLjPGm_IoVDMSc6ggeHBvVEwTkwpVTQOYY7H1L5EcujKMAX4AHzjprg7yBlvAe6Ax0zdRqnJcJr8sLpKcGb83lJflx__n51U91--_L16tNtZZquzRUfOsvE0LlG9rK3orhutBg02L6RTPZj7YztWyk5F0N_uoBsec-k5W3bday5JO_XvmXGX0uZRB0wGZiKMwhLUmIY6rrjshDrlWhiWUAEp-aIBx2PijN1Skjt1SkhdUporYkienfuvowHsP8k50gK4eNKgOLxHiGqZMp2DFiMZXvKBvxf_yeG4KVW</recordid><startdate>20051230</startdate><enddate>20051230</enddate><creator>Daiber, Andreas</creator><creator>Oelze, Matthias</creator><creator>Coldewey, Meike</creator><creator>Kaiser, K.</creator><creator>Huth, C.</creator><creator>Schildknecht, S.</creator><creator>Bachschmid, M.</creator><creator>Nazirisadeh, Y.</creator><creator>Ullrich, V.</creator><creator>Mülsch, A.</creator><creator>Münzel, T.</creator><creator>Tsilimingas, N.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051230</creationdate><title>Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure</title><author>Daiber, Andreas ; Oelze, Matthias ; Coldewey, Meike ; Kaiser, K. ; Huth, C. ; Schildknecht, S. ; Bachschmid, M. ; Nazirisadeh, Y. ; Ullrich, V. ; Mülsch, A. ; Münzel, T. ; Tsilimingas, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-185d0685f39797d60013a68aed739097b2fcd7499116877499e941709d1445503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aldehyde Dehydrogenase - antagonists & inhibitors</topic><topic>Aldehyde Dehydrogenase, Mitochondrial</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Cell Adhesion Molecules - biosynthesis</topic><topic>Drug Tolerance - physiology</topic><topic>Free Radical Scavengers - pharmacology</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Hydralazine</topic><topic>Hydralazine - pharmacology</topic><topic>Hydralazine - therapeutic use</topic><topic>Male</topic><topic>Microfilament Proteins - biosynthesis</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - metabolism</topic><topic>Mitochondrial Proteins - antagonists & inhibitors</topic><topic>Nitrate tolerance</topic><topic>Nitroglycerin - pharmacology</topic><topic>NO signaling</topic><topic>Organic nitrates</topic><topic>Oxidative Stress - drug effects</topic><topic>Peroxynitrite</topic><topic>Peroxynitrous Acid - antagonists & inhibitors</topic><topic>Peroxynitrous Acid - biosynthesis</topic><topic>Phosphoproteins - biosynthesis</topic><topic>Prognosis</topic><topic>Radical scavenger</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Reactive Nitrogen Species - metabolism</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Superoxide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daiber, Andreas</creatorcontrib><creatorcontrib>Oelze, Matthias</creatorcontrib><creatorcontrib>Coldewey, Meike</creatorcontrib><creatorcontrib>Kaiser, K.</creatorcontrib><creatorcontrib>Huth, C.</creatorcontrib><creatorcontrib>Schildknecht, S.</creatorcontrib><creatorcontrib>Bachschmid, M.</creatorcontrib><creatorcontrib>Nazirisadeh, Y.</creatorcontrib><creatorcontrib>Ullrich, V.</creatorcontrib><creatorcontrib>Mülsch, A.</creatorcontrib><creatorcontrib>Münzel, T.</creatorcontrib><creatorcontrib>Tsilimingas, N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daiber, Andreas</au><au>Oelze, Matthias</au><au>Coldewey, Meike</au><au>Kaiser, K.</au><au>Huth, C.</au><au>Schildknecht, S.</au><au>Bachschmid, M.</au><au>Nazirisadeh, Y.</au><au>Ullrich, V.</au><au>Mülsch, A.</au><au>Münzel, T.</au><au>Tsilimingas, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2005-12-30</date><risdate>2005</risdate><volume>338</volume><issue>4</issue><spage>1865</spage><epage>1874</epage><pages>1865-1874</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>The hemodynamic and anti-ischemic effects of nitroglycerin (GTN) are rapidly blunted as a result of the development of nitrate tolerance. Hydralazine has been shown to prevent tolerance in experimental and clinical studies, all of which may be at least in part secondary to antioxidant properties of this compound. The antioxidant effects of hydralazine were tested in cell free systems, cultured smooth muscle cells, isolated mitochondria, and isolated vessels. Inhibitory effects on the formation of superoxide and/or peroxynitrite formation were tested using lucigenin and L-012 enhanced chemiluminescence as well as DHE-fluorescence. The peroxynitrite scavenging properties were also assessed by inhibition of nitration of phenol. Prevention of impairment of NO downstream signaling and GTN bioactivation was determined by measurement of P-VASP (surrogate parameter for the activity of the cGMP-dependent kinase-I, cGK-I) and mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Hydralazine dose-dependently decreased the chemiluminescence signal induced by peroxynitrite from SIN-1 and by superoxide from HX/XO in a cell free system, by superoxide in smooth muscle cells and mitochondria acutely challenged with GTN. Moreover, hydralazine inhibited the peroxynitrite-mediated nitration of phenols as well as proteins in smooth muscle cells in a dose-dependent fashion. Finally, hydralazine normalized impaired cGK-I activity as well as impaired vascular ALDH-2 activity. Our results indicate that hydralazine is a highly potent radical scavenger. Thus, the combination with isosorbide dinitrate (ISDN) will favorably influence the nitroso-redox balance in the cardiovascular system in patients with congestive heart failure and may explain at least in part the improvement of prognosis in patients with chronic congestive heart failure.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16289107</pmid><doi>10.1016/j.bbrc.2005.10.106</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-291X |
| ispartof | Biochemical and biophysical research communications, 2005-12, Vol.338 (4), p.1865-1874 |
| issn | 0006-291X 1090-2104 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68822519 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aldehyde Dehydrogenase - antagonists & inhibitors Aldehyde Dehydrogenase, Mitochondrial Animals Antioxidants - pharmacology Antioxidants - therapeutic use Cell Adhesion Molecules - biosynthesis Drug Tolerance - physiology Free Radical Scavengers - pharmacology Heart Failure - drug therapy Humans Hydralazine Hydralazine - pharmacology Hydralazine - therapeutic use Male Microfilament Proteins - biosynthesis Mitochondria - drug effects Mitochondria - metabolism Mitochondrial Proteins - antagonists & inhibitors Nitrate tolerance Nitroglycerin - pharmacology NO signaling Organic nitrates Oxidative Stress - drug effects Peroxynitrite Peroxynitrous Acid - antagonists & inhibitors Peroxynitrous Acid - biosynthesis Phosphoproteins - biosynthesis Prognosis Radical scavenger Rats Rats, Wistar Reactive Nitrogen Species - metabolism Reactive Oxygen Species - metabolism Superoxide |
| title | Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T23%3A42%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydralazine%20is%20a%20powerful%20inhibitor%20of%20peroxynitrite%20formation%20as%20a%20possible%20explanation%20for%20its%20beneficial%20effects%20on%20prognosis%20in%20patients%20with%20congestive%20heart%20failure&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Daiber,%20Andreas&rft.date=2005-12-30&rft.volume=338&rft.issue=4&rft.spage=1865&rft.epage=1874&rft.pages=1865-1874&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2005.10.106&rft_dat=%3Cproquest_cross%3E68822519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68822519&rft_id=info:pmid/16289107&rft_els_id=S0006291X05023569&rfr_iscdi=true |